A S Chappell
Overview
Explore the profile of A S Chappell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
212
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zwart R, Sher E, Ping X, Jin X, Sims Jr J, Chappell A, et al.
J Pharmacol Exp Ther
. 2014 Jul;
351(1):124-33.
PMID: 25027316
Perampanel [Fycompa, 2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile hydrate 4:3; Eisai Inc., Woodcliff Lake, NJ] is an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonist used as an adjunctive treatment of partial-onset seizures. We asked whether perampanel has...
2.
Chappell A, Gonzales C, Williams J, Witte M, Mohs R, Sperling R
Neurology
. 2007 Mar;
68(13):1008-12.
PMID: 17389305
Objective: To investigate the efficacy and safety of the positive alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid modulator LY451395 in patients with mild to moderate Alzheimer disease (AD) (Mini-Mental State Examination scores 14 to...
3.
Jhee S, Chappell A, Zarotsky V, Moran S, Rosenthal M, Kim E, et al.
J Clin Pharmacol
. 2006 Mar;
46(4):424-32.
PMID: 16554450
The objective of this study was to measure the steady-state cerebrospinal fluid (CSF) concentration of LY450108 and LY451395 (positive modulators of AMPA receptors) in healthy subjects after the administration of...
4.
Sang C, Ramadan N, Wallihan R, Chappell A, Freitag F, Smith T, et al.
Cephalalgia
. 2004 Jun;
24(7):596-602.
PMID: 15196302
Glutamatergic hyperactivity is implicated migraine pathogenesis. Also, LY293558, an alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate (KA) receptor antagonist, is effective in preclinical models of migraine. We therefore tested LY293558 in acute migraine. We...
5.
Chappell A, Sander J, Brodie M, Chadwick D, Lledo A, Zhang D, et al.
Neurology
. 2002 Jun;
58(11):1680-2.
PMID: 12058100
The authors report a double-blind, placebo-controlled, crossover study of talampanel in 49 patients with refractory partial seizures. Three doses of talampanel were investigated based on differences in patients' concomitant antiepileptic...
6.
Chappell A
Semin Neurol
. 2002 Jan;
21(4):417-24.
PMID: 11774057
The revolution in neurological therapeutics means that an increasing number of neurologists will have the opportunity to participate in a drug development process that is long and complicated. The opportunity...
7.
Belayev L, Alonso O, Liu Y, Chappell A, Zhao W, Ginsberg M, et al.
J Neurotrauma
. 2001 Nov;
18(10):1031-8.
PMID: 11686490
Talampanel [(R)-7-acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-7H-1,3-dioxolo[4,5-h][2,3] benzodiazepine] is an orally active noncompetitive antagonist of the AMPA subtype of glutamate excitatory amino acid receptors. The purpose of this study was to determine whether treatment with...
8.
Gilron I, Max M, Lee G, Booher S, Sang C, Chappell A, et al.
Clin Pharmacol Ther
. 2000 Oct;
68(3):320-7.
PMID: 11014414
Background: Previous studies suggest that 2-amino-3-hydroxy-5-methyl-4-isoxazole-proprionic acid (AMPA)/kainate antagonists reduce experimentally induced pain. There have been no studies of AMPA/kainate antagonists in clinical pain. Methods: Analgesic efficacy of intravenous LY293558...
9.
Sang C, Hostetter M, Gracely R, Chappell A, Schoepp D, Lee G, et al.
Anesthesiology
. 1998 Nov;
89(5):1060-7.
PMID: 9821993
Background: Animal studies suggest that alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid-kainate (AMPA-KA) receptors are involved in pain processing. The effects of the competitive AMPA-KA antagonist LY293558 in two types of experimental pain in...
10.
Chappell A, Bay J, Botzum G, Cohen M
Neuropharmacology
. 1994 Mar;
33(3-4):509-13.
PMID: 7984290
Zatosetron (13 mg or 0.19 mg/kg), a potent and selective 5-HT3 receptor antagonist was studied with a 30 min infusion in a crossover double-blind placebo-controlled trial for acute migraine therapy....